2nd International Symposium on Clinical & Basic Investigation in Glioblastoma

 

Congress - Toledo, Spain

 

Glioblastoma multiforme (GBM) continues to be the most common and malignant primary brain tumor in adults carrying a dismal prognosis with less than 15 months median survival. Conventional therapy protocols used in this disease have low success rate and patients suffer tumor recurrence emphasizing the treatment resistant nature of GBMs. GBMs display remarkable intratumoral heterogeneity and cellular hierarchy morphologically. Glioma stem cells (GSC) are a population of cells within the bulk of the tumor with the capability to initiate and sustain tumour growth. They are also responsible of refractoriness to the current therapies. The development of new therapies targeting this GSC subpopulation is the most promising approach to fight GBM.
Advances in molecular technologies and studies at the genome, proteome and methylome-wide level have done possible to evaluate the most frequent genetic and epigenetic changes in glioblastoma and facilitated the identification of different GBM subgroups that are relevant for the clinical understanding of this type of cancer.
In the light of the new findings on GBM, this symposium will bring together the most recognized international and national clinicians and scientists to go over the current and upcoming GBM clinical treatment.

 

 

If you'd like to ask a question or post a comment about this talk please do so below.